Novavax, Inc. (NASDAQ:NVAX)’s traded shares stood at 3.33 million during the last session, with the company’s beta value hitting 2.04. At the close of trading, the stock’s price was $10.00, to imply a decrease of -1.19% or -$0.12 in intraday trading. The NVAX share’s 52-week high remains $23.86, putting it -138.6% down since that peak but still an impressive 64.7% since price per share fell to its 52-week low of $3.53. The company has a valuation of $1.60B, with an average of 8.01 million shares in intraday trading volume over the past 10 days and average of 6.80 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Novavax, Inc. (NVAX), translating to a mean rating of 2.60. Of 16 analyst(s) looking at the stock, 0 analyst(s) give NVAX a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 10 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.83.

Novavax, Inc. (NASDAQ:NVAX) trade information

After registering a -1.19% downside in the last session, Novavax, Inc. (NVAX) has traded red over the past five days. The 5-day price performance for the stock is -1.48%, and -24.76% over 30 days. With these gigs, the year-to-date price performance is 108.33%. Short interest in Novavax, Inc. (NASDAQ:NVAX) saw shorts transact 33.88 million shares and set a 5.19 days time to cover.

The extremes give us $14 and $174 for target low and target high price respectively. As such, NVAX has been trading -1640.0% off suggested target high and -40.0% from its likely low.

Novavax, Inc. (NVAX) estimates and forecasts

Looking at statistics comparing Novavax, Inc. share performance against respective industry, we note that the company has outperformed competitors. Novavax, Inc. (NVAX) shares are 140.96% up over the last 6 months, with its year-to-date growth rate higher than industry average at 83.36% against 17.40%. Revenue is forecast to grow 34.10% this quarter before jumping 87.50% for the next one. The rating firms project that company’s revenue will shrink -22.60% compared to the previous financial year.

Revenue forecast for the current quarter as set by 4 analysts is 65.77M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 192.07M.Earnings reports from the last fiscal year show that sales brought in 186.99M and 291.34M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -64.80% before dropping -34.10% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 11.55% for the past 5-year period. While 2024 is set for a 81.38% return in earnings, projections for the next 5 years are at 37.90% annually.

NVAX Dividends

Novavax, Inc. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Novavax, Inc. (NASDAQ:NVAX)’s Major holders

Novavax, Inc. insiders hold 4.38% of total outstanding shares, with institutional holders owning 54.16% of the shares at 56.64% float percentage. In total, 54.16% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 14.08 million shares (or 10.0599% of shares), all amounting to roughly $178.19 million.

The next major institution holding the largest number of shares is BLACKROCK INC. with 11.85 million shares, or about 8.4669% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $149.98 million.